The NF-KB pathway and endocrine therapy resistance in breast cancer

Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study

(2018) Norikazu Masuda et al.   CANCER SCIENCE

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

(2018) Hope S. Rugo et al.   CLINICAL CANCER RESEARCH

Overcoming endocrine resistance in hormone receptor–positive breast cancer

(2018) A. AlFakeeh et al.   Current Oncology

Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors

(2018) Jack Prescott et al.   Cells

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

(2018) Tarah J. Ballinger et al.   Frontiers in Oncology

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy

(2018) Jinfang Zhang et al.   TRENDS IN BIOCHEMICAL SCIENCES

Treatment for the endocrine resistant breast cancer: Current options and future perspectives

(2017) Chun-Yu Liu et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

The nuclear factor-kappa B pathway and response to treatment in breast cancer

(2017) Yeon Hee Park   PHARMACOGENOMICS

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

Endocrine treatment in breast cancer: Cure, resistance and beyond

(2016) Konstantinos Tryfonidis et al.   CANCER TREATMENT REVIEWS

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms

(2015) Jonna Frasor et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

TNFα Signaling Exposes Latent Estrogen Receptor Binding Sites to Alter the Breast Cancer Cell Transcriptome

(2015) Hector L. Franco et al.   MOLECULAR CELL

Frequent expression of PD-L1 on circulating breast cancer cells

(2015) Martine Mazel et al.   Molecular Oncology

Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

(2015) Kavitha Gowrishankar et al.   PLoS One

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

Emergence of Constitutively Active Estrogen Receptor-  Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer

(2014) R. Jeselsohn et al.   CLINICAL CANCER RESEARCH

NF-κB Signaling Is Required for XBP1 (Unspliced and Spliced)-Mediated Effects on Antiestrogen Responsiveness and Cell Fate Decisions in Breast Cancer

(2014) Rong Hu et al.   MOLECULAR AND CELLULAR BIOLOGY

Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications

(2013) F. Montemurro et al.   ANNALS OF ONCOLOGY

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

(2013) T. M. Herndon et al.   CLINICAL CANCER RESEARCH

The complexity of NF-κB signaling in inflammation and cancer

(2013) Bastian Hoesel et al.   Molecular Cancer

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) F. Cardoso et al.   ANNALS OF ONCOLOGY

Minireview: Inflammation: An Instigator of More Aggressive Estrogen Receptor (ER) Positive Breast Cancers

(2012) Sarah C. Baumgarten et al.   MOLECULAR ENDOCRINOLOGY

The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy

(2011) Suzanne E. Wardell et al.   BIOCHEMICAL PHARMACOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer

(2011) C. A. Lange et al.   ENDOCRINE-RELATED CANCER

Apoptosis in cancer: from pathogenesis to treatment

(2011) Rebecca SY Wong   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Inflammation meets cancer, with NF-κB as the matchmaker

(2011) Yinon Ben-Neriah et al.   NATURE IMMUNOLOGY

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estrogen Receptor Mutations and Changes in Downstream Gene Expression and Signaling

(2010) I. Barone et al.   CLINICAL CANCER RESEARCH

BCL2 and CASP8 regulation by NF-κB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells

(2010) Ruchi Nehra et al.   FASEB JOURNAL

Positive Cross-Talk between Estrogen Receptor and NF- B in Breast Cancer

(2009) J. Frasor et al.   CANCER RESEARCH

Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells

(2009) Robert Clarke et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

RelB NF- B Represses Estrogen Receptor   Expression via Induction of the Zinc Finger Protein Blimp1

(2009) X. Wang et al.   MOLECULAR AND CELLULAR BIOLOGY